(CTKB) Cytek Biosciences - Ratings and Ratios
Aurora,Northern-Lights,Sorters,Imagers,Reagents
EPS (Earnings per Share)
Revenue
Dividends
Currently no dividends paid| Risk via 5d forecast | |
|---|---|
| Volatility | 65.6% |
| Value at Risk 5%th | 94.5% |
| Relative Tail Risk | -12.44% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.03 |
| Alpha | -38.94 |
| CAGR/Max DD | -0.24 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.589 |
| Beta | 1.080 |
| Beta Downside | 0.841 |
| Drawdowns 3y | |
|---|---|
| Max DD | 82.03% |
| Mean DD | 52.07% |
| Median DD | 55.68% |
Description: CTKB Cytek Biosciences October 25, 2025
Cytek Biosciences, Inc. (NASDAQ:CTKB) develops and sells advanced cell-analysis instrumentation and reagents for biomedical research, drug discovery, and clinical applications. Its flagship platforms-Aurora and Northern Lights-use full-spectrum flow cytometry to enable high-dimensional phenotyping, while complementary products such as the Amnis ImageStream, Guava Muse/EasyCyte analyzers, and Orion reagent-cocktail systems broaden the addressable market across both research and clinical labs.
The company’s ecosystem includes automated sample-handling hardware (micro-sampling and loader systems), the SpectroFlo software suite for end-to-end data workflow, and a portfolio of cFluor-conjugated antibodies that are sold as consumables. Distribution is a mix of direct sales in North America, Europe, China, and APAC, supplemented by regional distributors in Latin America and the Middle East.
Key market metrics that shape Cytek’s outlook: (1) the global flow cytometry market is projected to grow at a ~8% CAGR through 2030, driven by expanding immuno-oncology pipelines and the rise of single-cell omics; (2) CTKB reported FY 2024 revenue of roughly $84 million, a 22% year-over-year increase, with cash and equivalents of $55 million, providing runway for R&D and international expansion; (3) the company’s R&D spend has risen to ~15% of revenue, reflecting its focus on full-spectrum and imaging flow technologies that differentiate it from legacy vendors such as BD and Thermo Fisher.
For a deeper, data-driven assessment of CTKB’s valuation and risk profile, you might find the analytical tools on ValueRay useful.
Piotroski VR‑10 (Strict, 0-10) 1.0
| Net Income (-12.8m TTM) > 0 and > 6% of Revenue (6% = 11.8m TTM) |
| FCFTA -0.01 (>2.0%) and ΔFCFTA -7.04pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 159.2% (prev 162.7%; Δ -3.55pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA -0.00 (>3.0%) and CFO -1.92m > Net Income -12.8m (YES >=105%, WARN >=100%) |
| NO Net Debt/EBITDA fails (EBITDA <= 0) |
| Current Ratio 5.17 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (127.5m) change vs 12m ago -3.94% (target <= -2.0% for YES) |
| Gross Margin 53.46% (prev 54.92%; Δ -1.46pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 39.92% (prev 40.96%; Δ -1.04pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio -15.74 (EBITDA TTM -18.1m / Interest Expense TTM 1.89m) >= 6 (WARN >= 3) |
Altman Z'' 2.85
| (A) 0.63 = (Total Current Assets 388.5m - Total Current Liabilities 75.2m) / Total Assets 494.9m |
| (B) -0.12 = Retained Earnings (Balance) -57.7m / Total Assets 494.9m |
| (C) -0.06 = EBIT TTM -29.8m / Avg Total Assets 493.1m |
| (D) -0.49 = Book Value of Equity -56.7m / Total Liabilities 116.3m |
| Total Rating: 2.85 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 35.05
| 1. Piotroski 1.0pt |
| 2. FCF Yield -1.52% |
| 3. FCF Margin -3.00% |
| 4. Debt/Equity 0.09 |
| 5. Debt/Ebitda 3.21 |
| 6. ROIC - WACC (= -14.91)% |
| 7. RoE -3.35% |
| 8. Rev. Trend 60.34% |
| 9. EPS Trend -19.94% |
What is the price of CTKB shares?
Over the past week, the price has changed by +7.23%, over one month by -13.70%, over three months by +35.85% and over the past year by -21.98%.
Is CTKB a buy, sell or hold?
- Strong Buy: 1
- Buy: 1
- Hold: 3
- Sell: 1
- Strong Sell: 0
What are the forecasts/targets for the CTKB price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 5.8 | 14.1% |
| Analysts Target Price | 5.8 | 14.1% |
| ValueRay Target Price | 4.9 | -3.4% |
CTKB Fundamental Data Overview December 19, 2025
P/E Forward = 370.3704
P/S = 3.1247
P/B = 1.6263
Beta = 1.295
Revenue TTM = 196.8m USD
EBIT TTM = -29.8m USD
EBITDA TTM = -18.1m USD
Long Term Debt = 655.0k USD (from longTermDebt, last quarter)
Short Term Debt = 12.9m USD (from shortTermDebt, last quarter)
Debt = 35.2m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -58.1m USD (from netDebt column, last quarter)
Enterprise Value = 388.5m USD (615.0m + Debt 35.2m - CCE 261.7m)
Interest Coverage Ratio = -15.74 (Ebit TTM -29.8m / Interest Expense TTM 1.89m)
FCF Yield = -1.52% (FCF TTM -5.90m / Enterprise Value 388.5m)
FCF Margin = -3.00% (FCF TTM -5.90m / Revenue TTM 196.8m)
Net Margin = -6.51% (Net Income TTM -12.8m / Revenue TTM 196.8m)
Gross Margin = 53.46% ((Revenue TTM 196.8m - Cost of Revenue TTM 91.6m) / Revenue TTM)
Gross Margin QoQ = 52.69% (prev 52.34%)
Tobins Q-Ratio = 0.78 (Enterprise Value 388.5m / Total Assets 494.9m)
Interest Expense / Debt = 1.40% (Interest Expense 494.0k / Debt 35.2m)
Taxrate = 29.49% (-2.29m / -7.77m)
NOPAT = -21.0m (EBIT -29.8m * (1 - 29.49%)) [loss with tax shield]
Current Ratio = 5.17 (Total Current Assets 388.5m / Total Current Liabilities 75.2m)
Debt / Equity = 0.09 (Debt 35.2m / totalStockholderEquity, last quarter 378.6m)
Debt / EBITDA = 3.21 (negative EBITDA) (Net Debt -58.1m / EBITDA -18.1m)
Debt / FCF = 9.84 (negative FCF - burning cash) (Net Debt -58.1m / FCF TTM -5.90m)
Total Stockholder Equity = 382.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -2.59% (Net Income -12.8m / Total Assets 494.9m)
RoE = -3.35% (Net Income TTM -12.8m / Total Stockholder Equity 382.9m)
RoCE = -7.77% (EBIT -29.8m / Capital Employed (Equity 382.9m + L.T.Debt 655.0k))
RoIC = -5.40% (negative operating profit) (NOPAT -21.0m / Invested Capital 389.1m)
WACC = 9.51% (E(615.0m)/V(650.2m) * Re(10.0%) + D(35.2m)/V(650.2m) * Rd(1.40%) * (1-Tc(0.29)))
Discount Rate = 10.0% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: -100.0 | Cagr: -1.22%
Fair Price DCF = unknown (Cash Flow -5.90m)
EPS Correlation: -19.94 | EPS CAGR: -7.91% | SUE: 0.13 | # QB: 0
Revenue Correlation: 60.34 | Revenue CAGR: 8.21% | SUE: 0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=-0.04 | Chg30d=-0.005 | Revisions Net=-1 | Analysts=2
EPS next Year (2026-12-31): EPS=-0.01 | Chg30d=-0.045 | Revisions Net=-1 | Growth EPS=-200.0% | Growth Revenue=+5.5%
Additional Sources for CTKB Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle